ArticleProgress in biomaterials2019
A new formulation of graphene oxide/fluconazole compound as a promising agent against Candida albicans.
Article in Progress in biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Article
- Fabrication of a sponge-like protein based hydrogel incorporating fluconazole against Candida species as a potential treatment for vulvovaginal candidiasis infection.Scientific reports · 2025Article
- Graphene nanomaterials: A new frontier in preventing respiratory fungal infections.Current medical mycology · 2025Review
- Comparison of Antimicrobial Properties of Graphene Oxide-Based Materials, Carbon Dots, and Their Combinations Deposited on Cotton Fabrics.International journal of molecular sciences · 2024Article
- The antimicrobial efficacy of nanographene oxide and double antibiotic paste per se and in combination: part II.BMC oral health · 2023Article
- Carbon nanostructures: a comprehensive review of potential applications and toxic effects.3 Biotech · 2022Review
- Molecular Mapping of Antifungal Mechanisms Accessing Biomaterials and New Agents to Target Oral Candidiasis.International journal of molecular sciences · 2022Review
- Fluconazole conjugated-gold nanorods as an antifungal nanomedicine with low cytotoxicity against human dermal fibroblasts.RSC advances · 2020Article
- Toxicological response of the model fungus Saccharomyces cerevisiae to different concentrations of commercial graphene nanoplatelets.Scientific reports · 2020Article
- Commonalities and Differences in the Transcriptional Response of the Model FungusFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans (C. albicans) belongs to the opportunistic fungal pathogens, which cause a wide spectrum of infections in immune-compromised patients. Graphene oxide (GO), a biocompatibility agent, has been reported to exhibit effective antimicrobial activity. In the present study, a graphene oxide/fluconazole (GO/Flu) compound was synthesized and characterized using Fourier transform infrared spectroscopy (FTIR) and Raman spectroscopy. The antifungal activity of GO/Flu was examined against fluconazole-resistant C. albicans (ATCC 10231) compared to GO and Flu using the broth microdilution method, according to CLSI protocol. DNA fragmentation was assessed through the antifungal mechanism of GO/Flu. The release of Fluin PBS medium was measured. Moreover, the cytotoxicity effect of GO/Flu on SW480 cell line was evaluated. Indeed, adhesion ability of C. albicans-treated GO/Flu against SW480 cell line was assessed. The minimum inhibitory concentration (MIC) of GO, Flu, and GO/Flu was determined at 800 µg/mL, 16 µg/mL, and 400-9 µg/mL, respectively. Notably, GO/Flu exhibited an intense antifungal activity compared to GO and Flu. In addition, GO/Flu showed much less cell toxicity against SW480 cell line than GO and Flu (P < 0.05). The release determination of Flu in PBS (pH 7.4) medium was 72.42%. GO/Flu reduced the adhesion ability of C. albicans to SW480 cell line significantly. DNA fragmentation assay indicated that GO/Flu potentially degraded the DNA of C. albicans and caused a fungicidal influence. According to the findings, GO/Flu could enhance the antifungal activity against C.albicans through DNA fragmentation with low cytotoxicity effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.